Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Total Non-Current Liabilities for 12 consecutive years, with $436.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 1.76% year-over-year to $436.5 million; the TTM figure through Mar 2026 stood at $436.5 million (up 1.76% YoY), while the FY2025 annual figure was $422.5 million, down 3.53% from the prior year.
• Total Non-Current Liabilities advanced to $436.5 million in Q1 2026 per RNAC's latest filing, from $422.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $451.0 million in Q3 2024 and bottomed at $32.6 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $276.9 million across 5 years, with a median of $407.7 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 58.94% — and 2024, when it jumped 1282.77%.
• Cartesian Therapeutics' Total Non-Current Liabilities stood at $52.9 million in 2022, then jumped by 729.6% to $439.0 million in 2023, then dropped by 0.23% to $438.0 million in 2024, then decreased by 3.53% to $422.5 million in 2025, then advanced by 3.3% to $436.5 million in 2026.
• Business Quant data shows RNAC's Total Non-Current Liabilities at $436.5 million in Q1 2026, $422.5 million in Q4 2025, and $407.7 million in Q3 2025.